

Supplemental Figure Legends:


Suppl Figure 1. Age Subgroup Analysis. The younger age group (16-20 years) was associated with better outcomes, compared to the other two age groups, although differences were not significant (p-value = 0.33, 0.21, 0.17 for comparisons on OS, EFS and DFS, respectively). The 16-20 age group had about 5% improvement in 3-year OS, EFS, and DFS, compared to the older age groups. Estimated 3-year OS was 77% (68-88) for 16-20 years old, 72% (65-80) for 21-29 years old, and 70% (60-81) for 30-39 years old.

Suppl. Figure 2. Immunophenotype Subgroup Analysis. No significant differences were identified between B-cell and T-cell patients in clinical outcomes. Estimated 3-year OS was 74% (68-80) for B-cell patients and 68% (58-80) for T-cell patients (p-value = 0.40). Estimated 3-year EFS was 60% for both B-cell and T-cell patients (p-value = 0.66). Estimated 3-year DFS was 67% for B-cell and 65% for T-cell patients (p-value = 0.94)


Suppl. Figure 3. CD20 subset analysis: 175 B-cell ALL patients were evaluable for survival based on lymphoblast CD20 expression levels. There was no difference in OS, EFS, or DFS based on strong (>20%), low/moderate (<20%) or absent CD20 expression.

Suppl. Figure 4. Survival after relapse: 90 patients relapsed after remission and were included in the estimation of the survival after relapse (SAR). The median SAR was 10 months (95% CI, 7-14).


Overall Survival by Age




Event Free Survival by Age




Disease Free Survival by Age




Overall Survival by Immunophenotype




Event Free Survival by Immunophenotype




Disease Free Survival by Immunophenotype




Overall Survival by CD20 Groups



Event Free Survival by CD20 Groups



Disease Free Survival by CD20 Groups



Survival after Relapse (SAR)

